{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.6","upperLimit":"53.1","value":"43.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"}],"units":"Participants"}],"description":"For the relapsed/refractory peripheral T-cell lymphoma (PTCL) cohort, objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), assessed by blinded independent central review (BICR), among participants with centrally confirmed PTCL eligible histology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered valemetostat tosylate at a dose of 200 mg/day and had an eligible peripheral T-cell lymphoma .","id":"OG000","title":"Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set for Cohort 1 is defined as all subjects who received at least 1 dose of valemetostat tosylate and had an eligible PTCL subtype that was confirmed by central hematopathology review.","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression or death (whichever occurs first), up to approximately 23 months","title":"Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}